Would be interesting to see/hear come the 2013 AGM just how MSB...

Would be interesting to see/hear come the 2013 AGM just how MSB approaches things now with the likes of the FDA given this potentially substantial announcement.

COULD it be that we MAY see (among others) the T2D product hit the (huge and growing) market based on the current round of studies, because it really is, to the best of my LIMITED knowledge, the first (and currently only) genuine treatment for the condition, as opposed to simply masking its impact for a time.

Perhaps what we're really seeing here, is breakthrough treatments progressing from Ph2 to a merged Ph3/4 type situation of getting apparently safe and effective treatments into the marketplace and then following up with a cross-section of patients to get ongoing feedback and performance data "in the field".

A genuinely intelligent move from the FDA - so long as applied with professional consideration of course and potentially a real fast track for key MSB product.

Would be great to hear, in due course, what the company thinks of this potential?

They've been injecting these cells into peoples hearts now for years!